Clinical Trial Update: Peg Interferon α-2b for Relapsed Hematological Malignancies After Allo-HSCT [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 clinical trial of pegylated interferon alpha-2b for relapsed hematological malignancies after allogeneic hematopoietic stem cell transplantation has…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematological Neoplasms

Drugs mentioned

• Peg Interferon α-2b (pegylated interferon alpha-2b)

Snippet

Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Conditions: Hematological Neoplasms, Recurrence | Phase 2, Phase 3 | Status: COMPLETED